The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes
- 1 November 2004
- journal article
- review article
- Published by Elsevier in Kidney International
- Vol. 66 (92), S105-S107
- https://doi.org/10.1111/j.1523-1755.2004.09225.x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Role of Advanced Glycation End Products in Diabetic NephropathyJournal of the American Society of Nephrology, 2003
- The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetesThe FASEB Journal, 2003
- Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic NephropathyDiabetes, 2002
- Angiotensin II Receptor Antagonists and Angiotensin-Converting Enzyme Inhibitors Lower In Vitro the Formation of Advanced Glycation End ProductsJournal of the American Society of Nephrology, 2002
- Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic ratKidney International, 2002
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Ischemic acute renal failure: Long-term histology of cell and matrix changes in the ratKidney International, 2000
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyThe Lancet, 2000
- Accumulation of Maillard reaction products in skin collagen in diabetes and aging.Journal of Clinical Investigation, 1993
- Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic RatDiabetes, 1991